Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...

Moreover, Novo Nordisk's management has indicated that another product, amycretin, may demonstrate superior efficacy compared to CagriSema, with promising tolerance levels observed in early-phase ...

Moreover, Novo Nordisk's management has indicated that another product, amycretin, may demonstrate superior efficacy compared to CagriSema, with promising tolerance levels observed in early-phase ...

The drug, called amycretin and codenamed NN9487, is a dual agonist that targets both GLP-1 and amylin and is being developed in both oral and subcutaneous injection formulations. The oral form has ...

The new results with a once-weekly subcutaneous injection of amycretin – which is also being developed in a daily oral formulation – show that the combined GLP-1 and amylin agonist achieved up ...

amycretin and [a] once-weekly GIP/GLP-1 co-agonist. Moving to obesity and the first half of '25, we are now expecting to submit ... semaglutide (25 milligrams) for people with obesity to the U.S ...

In addition, Novo Nordisk recently announced promising trial results for its obesity treatment, amycretin. BMO Capital Markets reaffirmed their positive stance on the pharmaceutical giant in light of ...